The newly-launched program, led by Canadian non-profit TheraPsil, is the world’s
largest medical psilocybin access and data project

VANCOUVER, BC, July 28, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced its participation in Project Solace, the world’s largest medical psilocybin access and data project. Project Solace is led by TheraPsil in collaboration with Drug Science. Filament has enrolled in the project as a Health Canada-licensed producer of psilocybin.

“We are grateful for Filament Health’s support of Project Solace,” said Therapsil CEO Spencer Hawkswell. “There are a limited number of Health Canada-approved psilocybin suppliers so Filament’s participation greatly enhances the likelihood of patient access to much-needed drug candidates.”

The objectives of Project Solace are two-fold. The primary objective is to expand legal access to psilocybin for Canadian patients suffering from end-of-life distress and other serious conditions for which traditional treatment options have failed. The secondary objective is to develop a body of evidence using a real-world data registry which documents clinical effectiveness, safety, and clinician- and patient-reported outcomes from psilocybin-assisted psychotherapy through Health Canada’s Special Access Program or under exemptions authorizing possession of psilocybin.

“Project Solace represents an important opportunity to gain information regarding patient and clinician experiences with our drug candidates,” said Filament Health CEO, Benjamin Lightburn. “Gathering this data will not only support our drug development program, it will also facilitate decision-making surrounding the regulatory system for the future of medicalized psilocybin.”

For more information about Project Solace, visit the Project Solace website.


Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at and on Twitter, Instagram, and LinkedIn.


TheraPsil is a Canadian non-profit dedicated to advocating for patients in medical need of psilocybin and psilocybin-assisted psychotherapy. Learn more at


Certain statements and information contained herein may constitute “forward‐looking statements” and “forward‐looking information,” respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐ looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE Filament Health Corp.

For further information: MEDIA RELATIONS: Anna Cordon, Director of Communications, 778.245.9067, [email protected]; INVESTOR RELATIONS: [email protected]

Source link

Leave a Reply